News & Media

NEW YORK, October 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same…

NEW YORK, October 23, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major new contract with one of the United Kingdom’s largest industrial service providers.  The multinational company, a global leader operating across the energy,…

Time: 4PM AEDT | 9AM GST | 2PM JST | 10:30AM IST Discover a faster, non-invasive, and more efficient approach to workplace drug testing. See firsthand how fingerprint drug testing streamlines sample collection, reduces labor, and improves compliance. Explore the limitations and challenges of traditional workplace drug testing methods, including urine and saliva. See how…

NEW YORK, September 26, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today is providing an update on the timeline for anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System for the opiate codeine.    Following recent…

In December 2024, INBS submitted its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and

NEW YORK, August 06, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its Additional Information (“AI”) response to the United States Food and Drug Administration (“FDA”) as part of its ongoing 510(k) clearance process for planned entry to…

NEW YORK, July 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London’s largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. INBS’s…

NEW YORK, July 23, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission. “Our ongoing dialogue with…

NEW YORK, July 16, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution agreement with SMARTOX®, a Texas-based leader in drug and alcohol screening services, to bring its SmarTest Patch drug detection product to international markets outside of…

NEW YORK, July 15, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The SmarTest Patch is an innovative wearable device, developed by SMARTOX®, that enables…

NEW YORK, July 17, 2025 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic (“PK”) study data at the Association for Diagnostics and Laboratory Medicine (“ADLM”) 2025 Clinical Lab Expo, taking place July 27–31 in Chicago,…